Clinical Trial Details


Research Study Summary

A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis


This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).

To Learn more

CW ID: 212061
Date Last Changed: March 8, 2016

Clinical Trial Snapshot

Both Male and Female
18 to 55 Years
Overall Status
Lead Sponsor
Hoffmann-La Roche
Facility Type


Inclusion Criteria:

  • Diagnosis of RMS in accordance with the revised McDonald criteria
  • Received at least 1 previous immunization against TT or tetanus and diphtheria (DT/Td) or tetanus, diphtheria, and acellular pertussis (DTaP/Tdap)
  • Expanded disability status scale (EDSS) at baseline from 0 to 5.5 points, inclusive
  • For sexually active participants with reproductive potential, use of reliable means of contraception

Exclusion Criteria:

  • Contraindications for or intolerance to oral or intravenous corticosteroids, including intravenous methylprednisolone, according to the country label
  • Known presence of other neurologic disorders
  • Treatment with any investigational agent within 24 weeks of screening or 5 half-lives of the investigational drug, whichever is longer, or treatment with any experimental procedure for multiple sclerosis (MS)

More Info

Protocol Number: BN29739


Bradlee McCoy
University of South Florida- Morsani Center for Advanced Healthcare
13330 USF Laurel Drive
Tampa, FL 33613
Phone: 813-974-9423

View Map

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.